May 2023 OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)
May 2023 OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab
April 2023 OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
April 2023 OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 2023 OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio at the 2023 American Association for Cancer Research Annual Meeting
March 2023 OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology at the 2023 American Association for Cancer Research (AACR)
March 2023 OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies
February 2023 OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
February 2023 OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies